Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATP4A | P20648 | 2/20 | 0.40 |
| ▸ | ATP4B | P51164 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656700 | 0.93 | NPC1 (0.42) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL4655649 | 0.92 | NPC1 (0.42) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL4658007 | 0.92 | NPC1 (0.42) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL4656607 | 0.92 | NPC1 (0.42) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL5423067 | 0.91 | NPC1 (0.41) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL5428290 | 0.91 | NPC1 (0.41) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL4655587 | 0.91 | NPC1 (0.41) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL4790526 | 0.91 | NPC1 (0.40) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL10098815 | 0.91 | NPC1 (0.41) | NPC1GFERGRM1THRATHRB | |
| SCHEMBL4656448 | 0.91 | NPC1 (0.41) | NPC1GFERGRM1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996565-A2 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES WITH ANTI-HCV ACTIVITY | Achillion Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2007103550-A2 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES WITH ANTI-HCV ACTIVITY | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| EP-2460800-A1 | Substituted aminothiazole derivatives with anti-HCV activity | Achillion Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2460800-A1 | Substituted aminothiazole derivatives with anti-HCV activity | Achillion Pharmaceuticals, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| US-8106209-B2 | Substituted aminothiazole prodrugs of compounds with anti-HCV activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106209-B2 | Substituted aminothiazole prodrugs of compounds with anti-HCV activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | BCAT1, CCNT1, EIF2AK2 | NPC1 1930/4885GFER 994/4885GRM1 3288/4885 |
| US-20070213301-A1 | Substituted Aminothiazole Derivatives With Anti-HCV Activity | EIF2AK2, BCAT1, IL4I1 | NPC1 1995/4885GFER 1257/4885GRM1 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.